000 01413 a2200421 4500
005 20250511202959.0
264 0 _c19920122
008 199201s 0 0 eng d
022 _a0040-6376
024 7 _a10.1136/thx.46.10.706
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aWiselka, M J
245 0 0 _aProphylactic intranasal alpha 2 interferon and viral exacerbations of chronic respiratory disease.
_h[electronic resource]
260 _bThorax
_cOct 1991
300 _a706-11 p.
_bdigital
500 _aPublication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650 0 4 _aAdministration, Intranasal
650 0 4 _aAdult
650 0 4 _aAged
650 0 4 _aAsthma
_xcomplications
650 0 4 _aBronchitis
_xcomplications
650 0 4 _aChronic Disease
650 0 4 _aDouble-Blind Method
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aInterferon Type I
_xadverse effects
650 0 4 _aMale
650 0 4 _aMiddle Aged
650 0 4 _aRecombinant Proteins
650 0 4 _aRespiratory Tract Infections
_xcomplications
650 0 4 _aVirus Diseases
_xprevention & control
700 1 _aNicholson, K G
700 1 _aKent, J
700 1 _aCookson, J B
700 1 _aTyrrell, D A
773 0 _tThorax
_gvol. 46
_gno. 10
_gp. 706-11
856 4 0 _uhttps://doi.org/10.1136/thx.46.10.706
_zAvailable from publisher's website
999 _c1756413
_d1756413